RET and non-small cell lung carcinoma: The ORR of previously treated RET+ NSCLC patients on selpercatinib and pralsetinib were 64% and 61%, respectively, while the median PFS of previously treated patients on these two RET inhibitors was 16.5 months and 17.1 months, respectively [21, 22].